PROKIDNEY CORP. (PROK) Form 8-K — Nov 9, 2026
$PROKForm 8-KItems 2.02, 7.01, 8.01, 9.01Filed Nov 9, 2026, 7:00 AM ET0001193125-26-452616Original filing
ProKidney filed an 8-K reporting cash, cash equivalents and marketable securities of $141.9 million as of September 30, 2026. The filing also furnished an updated investor presentation reaffirming key milestones: full PROACT 1 Phase 3 enrollment (over 500 patients) expected in Q1 2027, topline eGFR slope data in Q2 2027, BLA submission in Q1 2028, and potential accelerated approval and launch in 1H 2029.
Key figures
- Cash Position
- 141900000
- Shares Outstanding
- 302381712
- Cash runway
- into mid-2027
- Bla submission
- Q1 2028
- Patent families
- 23
- Analyst coverage firms
- 7
- Proact1 topline readout
- Q2 2027
- Patents and applications
- 450+
- Proact1 enrollment target
- over 500 patients (up from 470)
- Accelerated approval launch
- 1H 2029
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.